| Not Yet Recruiting | Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine NCT07374510 | Sinovac Life Sciences Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Ye NCT06700148 | CanSino Biologics Inc. | Phase 3 |
| Active Not Recruiting | A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (C NCT06131554 | CanSino Biologics Inc. | Phase 3 |
| Unknown | A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine NCT06337071 | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year NCT06226714 | CanSino Biologics Inc. | Phase 3 |
| Completed | Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5) NCT03964012 | Serum Institute of India Pvt. Ltd. | Phase 3 |
| Completed | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers NCT02955797 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 NCT03077438 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Unknown | Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to NCT02919293 | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Completed | Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea NCT02864927 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Year NCT02842866 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate NCT02842853 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Hea NCT02640404 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine NCT02752906 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federa NCT02699840 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Year NCT02633787 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects NCT02591290 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Unknown | A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vacc NCT02481232 | Lanzhou Institute of Biological Products Co., Ltd | Phase 1 |
| Completed | Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Stud NCT02500511 | JN-International Medical Corporation | — |
| Completed | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddle NCT03205358 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adoles NCT02199691 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Va NCT01897402 | JN-International Medical Corporation | Phase 2 |
| Completed | Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the C NCT01894919 | Novartis Vaccines | Phase 3 |
| Completed | A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Hea NCT01478347 | Novartis Vaccines | Phase 3 |
| Completed | Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older NCT01732627 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Ol NCT01717638 | Novartis Vaccines | Phase 3 |
| Completed | Comparison of Two Meningococcal ACWY Conjugate Vaccines NCT01192997 | Public Health England | Phase 2 / Phase 3 |
| Completed | Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese NCT01519713 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines W NCT01466387 | Novartis | Phase 3 |
| Completed | Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Men NCT01482052 | JN-International Medical Corporation | Phase 1 |
| Completed | Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate V NCT01453348 | Novartis Vaccines | Phase 3 |
| Completed | A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When NCT01424644 | Novartis | Phase 4 |
| Completed | Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vacci NCT01434680 | Novartis | Phase 2 |
| Completed | Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Differen NCT01423084 | Novartis | Phase 3 |
| Completed | Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenAC NCT01367158 | Novartis Vaccines | Phase 2 |
| Completed | A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis NCT01339923 | Novartis Vaccines | Phase 3 |
| Completed | A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety NCT01274897 | Novartis Vaccines | Phase 3 |
| Completed | Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents NCT01210885 | Novartis Vaccines | Phase 2 |
| Completed | Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial V NCT01239043 | Sanofi | Phase 2 |
| Completed | Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a NCT01214837 | Novartis Vaccines | Phase 3 |
| Completed | Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study NCT01148524 | Novartis Vaccines | Phase 2 / Phase 3 |
| Completed | Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine NCT01148017 | Novartis Vaccines | Phase 3 |
| Completed | A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY NCT01018732 | Novartis Vaccines | Phase 2 |
| Completed | Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-mo NCT00937521 | Novartis Vaccines | Phase 2 |
| Completed | Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at NCT00944034 | Novartis Vaccines | Phase 2 / Phase 3 |
| Completed | Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Recei NCT00856297 | Novartis Vaccines | Phase 3 |
| Completed | Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine i NCT00667602 | Novartis Vaccines | Phase 3 |
| Completed | Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ NCT00874549 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents NCT00518180 | Novartis Vaccines | Phase 3 |
| Completed | Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers NCT00483574 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults NCT00474487 | Novartis Vaccines | Phase 3 |
| Completed | A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolesce NCT00450437 | Novartis Vaccines | Phase 3 |
| Completed | Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers NCT00422292 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL NCT00355121 | Sanofi | Phase 2 |
| Completed | A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers NCT00384397 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate NCT00329901 | Novartis Vaccines | Phase 3 |
| Completed | Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine NCT00994695 | Armauer Hansen Research Institute, Ethiopia | Phase 2 |
| Completed | Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months) NCT00310856 | Novartis Vaccines | Phase 2 |
| Completed | Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Mont NCT00310817 | Novartis Vaccines | Phase 2 |